Laroprovstat

Short Description:

API’s Name CAS No. US DMF Patent Expiry Date( U.S) Current Status 
Laroprovstat 2455427-91-3  2027 Jan.23, 2040

 

[Indication] 

1. Hypercholesterolemia: For the reduction of low-density lipoprotein cholesterol (LDL-C) in adult patients with hypercholesterolemia, as an adjunct to statin therapy.

2. Dyslipidemia: For the management of dyslipidemia in adult patients.

3. Cardiovascular Disease: For the reduction of cardiovascular risk in patients with atherosclerotic cardiovascular disease (ASCVD).


Product Detail

Product Tags


  • Previous:
  • Next:

  • Write your message here and send it to us